Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | MAX | P61244 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514454 | 0.80 | SLC16A3 (0.45) | SMN1; SMN2MEN1KMT2ALMNAESR1 | |
| SCHEMBL24038948 | 0.79 | MAPT (0.56) | SMN1; SMN2MEN1KMT2ALMNAPOLB | |
| SCHEMBL13425461 | 0.77 | MEN1 (0.53) | SMN1; SMN2MEN1KMT2ALMNANPC1 | |
| SCHEMBL20600283 | 0.77 | MAPK14 (0.47) | SMN1; SMN2MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL22613652 | 0.77 | MAPT (0.44) | SMN1; SMN2MEN1KMT2ALMNAPOLB | |
| SCHEMBL4683641 | 0.76 | NPBWR1 (0.47) | SMN1; SMN2MAPT | |
| SCHEMBL15638530 | 0.76 | ALDH1A1 (0.44) | SMN1; SMN2MEN1KMT2ALMNANPC1 | |
| SCHEMBL513268 | 0.75 | SLC16A3 (0.42) | SMN1; SMN2MEN1KMT2ALMNAESR1 | |
| SCHEMBL24828268 | 0.75 | CYP11B1 (0.41) | MAPTALDH1A1KDM4E | |
| SCHEMBL10475753 | 0.74 | NPC1 (0.45) | SMN1; SMN2MEN1KMT2ALMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | SMN1; SMN2 411/4885MEN1 483/4885KMT2A 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.